That 57% gap is not an anomaly. It is the structural pricing difference between America’s two outpatient surgery settings — and it is the single most underused fact in healthcare consumer economics.
The 45% number
The research is unambiguous. Studies have consistently shown that the same procedure performed at an ambulatory surgery center costs 25 to 75 percent less than at a hospital outpatient department. A Grand View Research analysis of lumbar decompression surgery put numbers to it: patients treated in ASCs incurred an average one-year episode-of-care cost of $5,662, versus $10,229 at hospital outpatient departments — nearly 45% lower total treatment costs.
The savings come from lower facility fees and leaner operations, not from cutting corners. The same study reported no statistically significant differences between ASCs and hospitals in emergency department visits within 90 days, readmission rates, reoperation rates, postoperative complications, or overall recovery outcomes. On a cost-effectiveness basis — dollars per quality-adjusted life year gained — ASCs came in at $64,873 versus $152,630 for hospital outpatient surgery. More than twice as cost-effective, with equivalent clinical results.
The American Journal of Managed Care published the definitive commercial-insurance analysis in October 2025. Comparing insurer-paid amounts across a 50-state claims sample: insurers paid $1,042 — 110% — more to an in-network hospital outpatient department than to an in-network ASC for the same procedures. Patients paid $186 more out of pocket at the hospital. The cheapest option in every comparison was the in-network ASC; the most expensive, the out-of-network hospital department, at nearly double.
Why the gap exists
Hospitals are expensive to run. They maintain emergency departments, intensive care units, trauma bays, and round-the-clock staffing — fixed costs that get allocated across every service line, including the outpatient knee scope that uses none of them. ASCs are purpose-built for same-day procedures: narrower scope, standardized workflows, no overnight beds, no ER. Their cost structure is simply lighter.
Medicare recognized this decades ago and pays ASCs at a lower rate than hospitals for identical procedures — a policy called site-neutral payment that commercial insurers have increasingly adopted. Some insurers now offer reduced cost-sharing to patients who choose ASCs, creating a direct financial incentive. The logic is unassailable: why pay hospital prices for non-hospital care?
The scale of the shift is staggering. ASCs now host 72% of all U.S. surgeries, per industry data — one of the most significant practice-environment changes in modern medicine. Patient satisfaction at ASCs averages 92%, according to ASCA data. Wait times run roughly 20% shorter. Scheduling is about 25% more efficient. This is not a niche alternative. It is where most surgery happens.
And CMS keeps expanding the frontier. The agency’s 2026 proposal would add 276 procedures to the ASC covered-procedures list — including high-demand cardiovascular, spine, and vascular procedures. Each addition moves another slice of surgical volume from the $10,229 setting to the $5,662 setting. Medicare alone saves an estimated $4 billion a year from the ASC shift.
The counterargument: what ASCs cannot do
The discount has boundaries, and honest accounting requires naming them. ASCs are designed for patients who can safely go home the same day. Complex cases — significant comorbidities, high anesthesia risk, procedures with meaningful bleeding risk — belong in hospitals, where the ICU is down the hall rather than across town. The 45% savings figure applies to appropriately selected patients; cherry-picking the healthiest cases flatters the comparison, though the studies control for this.
Physician ownership raises a second concern. Many ASCs are partly owned by the surgeons who operate in them, creating a financial incentive to recommend surgery — and to recommend the ASC over the hospital. Federal Stark Law exceptions permit this structure, and accreditation standards govern it, but the self-referral risk is real and documented. A surgeon who profits from the facility fee may see surgical indications more generously.
Third, the hospital cross-subsidy problem. Hospital outpatient departments lose money on some services and make it on others; the profitable outpatient procedures help fund the money-losing emergency department that the ASC down the street does not operate. Siphon all the profitable volume to ASCs and the hospital’s economics deteriorate — potentially threatening the very emergency capacity the community depends on. This is the strongest argument against unchecked migration, and it deserves more attention than it gets.
The practical playbook
For patients facing an outpatient procedure, the decision tree is straightforward. First, ask whether your procedure is ASC-eligible — most arthroscopies, cataract surgeries, colonoscopies, hernia repairs, and increasingly joint replacements are. Second, get quotes from both settings, in-network, and compare your out-of-pocket — not the billed charges, which are fiction, but the allowed amount and your cost-share. Third, check your surgeon’s ASC privileges; the best outcome is the same surgeon at the cheaper site.
For employers and benefits designers, the AJMC findings point to a clear strategy: steerage works. Benefit designs that waive or reduce cost-sharing for ASC selection — already adopted by some large employers — move volume without restricting choice. The patient saves $186; the plan saves $1,042; the surgeon operates in a setting with 92% satisfaction. It is the rare healthcare intervention where every party wins.
The deeper lesson is about price transparency’s limits. The hospital price transparency data now reveals these gaps — that was the point of the regulation. But data without decision architecture does not change behavior. Nobody told the Texas patient about the $7,900 option until she asked. The information existed. The nudge did not.
In 2026, the cheapest surgery is often the same surgery, by the same surgeon, in a different building. The healthcare system knows this. Your insurer knows this. The question is whether anyone tells you before you schedule.
The definitive source for surgery rate intelligence is still up for grabs. SurgeryRates.com is available for acquisition by the company that will own this category — inquiries to info@primedomaincapital.com.
- "What is your self-pay cash price for CPT [codes]?" Get it in writing before the procedure. Many hospitals offer 20–40% prompt-pay discounts off billed charges; some match their posted cash price only if you ask.
- "Can you provide a good-faith estimate?" The No Surprises Act entitles uninsured and self-pay patients to a written good-faith estimate before scheduled care. If the final bill exceeds the estimate by $400 or more, you can dispute it through the federal patient-provider dispute process.
- "Is the anesthesiologist / assistant surgeon / pathologist in my network?" Facility price is only part of the bill. Out-of-network ancillary providers were the classic surprise-billing trap; the No Surprises Act now protects against most of it, but verify anyway.
- "What is bundled in this price, and what is billed separately?" Implant, facility fee, surgeon fee, anesthesia — get the itemization. Two quotes that look $5,000 apart may be identical once you learn one excludes anesthesia.
- If I pay cash instead of running this through insurance, what is the total — and will it count toward my deductible? (Usually not. Do the math both ways.)
- Is there a less expensive site of service where my surgeon also operates?
- What is your financial assistance policy, and what income threshold qualifies? (Nonprofit hospitals must have one. Many patients who qualify never apply.)
- Can I get the estimate and the cash price in writing before I schedule?
The price of your surgery is knowable before the incision. SurgeryRates.com compiles facility-level pricing so you can compare before you schedule — not after the bill arrives.